

In re Application of: Gera NEUFELD
Serial No.: 10/539,289
Filed: June 16, 2005
Office Action Mailing Date: January 23, 2008

Examiner: Zachary C. HOWARD
Group Art Unit: 1646
Attorney Docket: 29432

WHAT IS CLAIMED IS:

1. (Currently amended) An isolated VEGF₁₄₅ polypeptide consisting of the amino acid sequence set forth in SEQ ID NO:4 ~~devoid of a VEGFR-1 binding activity.~~

2-3. (Cancelled)

4. (Withdrawn) An isolated polynucleotide comprising a nucleic acid sequence encoding a VEGF₁₄₅ polypeptide devoid of a VEGFR-1 binding activity.

5. (Withdrawn) The isolated polynucleotide of claim 4, wherein said polynucleotide is set forth by SEQ ID NO:2.

6. (Withdrawn) The isolated polynucleotide of claim 4, wherein said polynucleotide is at least 90 % homologous to the polynucleotide sequence set forth by SEQ ID NO:1 as determined using the BlastN software of the National Center of Biotechnology Information (NCBI) using default parameters.

7. (Withdrawn) The isolated polynucleotide of claim 4, wherein said VEGF₁₄₅ polypeptide exhibits a VEGFR-2 binding activity.

8. (Withdrawn) A nucleic acid construct comprising the isolated polynucleotide of claim 4.

9. (Withdrawn) The nucleic acid construct of claim 8, further comprising a promoter for directing expression of the isolated polynucleotide in mammalian cells.

In re Application of: Gera NEUFELD
Serial No.: 10/539,289
Filed: June 16, 2005
Office Action Mailing Date: January 23, 2008

Examiner: Zachary C. HOWARD
Group Art Unit: 1646
Attorney Docket: 29432

10. (Withdrawn) The nucleic acid construct of claim 9, wherein said promoter is an endothelial cell specific promoter.

11. (Withdrawn) A method of promoting re-endothelialization in a tissue of an individual comprising providing to the tissue of the individual a VEGF₁₄₅ polypeptide exhibiting a VEGFR-2 binding activity and lacking a VEGFR-1 binding activity thereby promoting re-endothelialization in the tissue of the individual.

12. (Withdrawn) The method of claim 11, wherein said tissue is selected from the group consisting of an artery and a vein.

13. (Withdrawn) The method of claim 11, wherein said VEGF₁₄₅ polypeptide is set forth by SEQ ID NO:4.

14. (Withdrawn) The method of claim 11, wherein said providing is effected by administering said VEGF₁₄₅ polypeptide into the tissue of the individual.

15. (Withdrawn) The method of claim 11, wherein said providing is effected by expressing a polynucleotide encoding said VEGF₁₄₅ polypeptide in the tissue of the individual.

16. (Withdrawn) The method of claim 15, wherein said polynucleotide is set forth by SEQ ID NO:2.

17. (Withdrawn) The method of claim 15, wherein said polynucleotide at least 90 % homologous to the polynucleotide sequence set forth in SEQ ID NO:1 as determined using the BlastN software of the National Center of Biotechnology Information (NCBI) using default parameters.

In re Application of: Gera NEUFELD
Serial No.: 10/539,289
Filed: June 16, 2005
Office Action Mailing Date: January 23, 2008

Examiner: Zachary C. HOWARD
Group Art Unit: 1646
Attorney Docket: 29432

18. (Withdrawn) A method of preventing and/or treating restenosis in an individual in need thereof comprising providing to the individual a VEGF₁₄₅ polypeptide exhibiting a VEGFR-2 binding activity and lacking a VEGFR-1 binding activity thereby preventing and/or treating restenosis in the individual in need thereof.

19. (Withdrawn) The method of claim 18, wherein said VEGF₁₄₅ polypeptide is set forth by SEQ ID NO:4.

20. (Withdrawn) The method of claim 18, wherein said providing is effected by administering said VEGF₁₄₅ polypeptide into the individual.

21. (Withdrawn) The method of claim 18, wherein said providing is effected by expressing a polynucleotide encoding said VEGF₁₄₅ polypeptide in an artery and/or a vein of the individual.

22. (Withdrawn) The method of claim 21, wherein said polynucleotide is set forth by SEQ ID NO:2.

23. (Withdrawn) The method of claim 21, wherein said polynucleotide at least 90 % homologous to the polynucleotide sequence set forth in SEQ ID NO:1 as determined using the BlastN software of the National Center of Biotechnology Information (NCBI) using default parameters.